1
|
Ozturk H, Cingoz H, Tufan T, Yang J, Adair SJ, Tummala KS, Kuscu C, Kinali M, Comertpay G, Nagdas S, Goudreau BJ, Luleyap HU, Bingul Y, Ware TB, Hwang WL, Hsu KL, Kashatus DF, Ting DT, Chandel NS, Bardeesy N, Bauer TW, Adli M. ISL2 is a putative tumor suppressor whose epigenetic silencing reprograms the metabolism of pancreatic cancer. Dev Cell 2022; 57:1331-1346.e9. [PMID: 35508175 DOI: 10.1016/j.devcel.2022.04.014] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2021] [Revised: 03/11/2022] [Accepted: 04/08/2022] [Indexed: 12/17/2022]
Abstract
Pancreatic ductal adenocarcinoma (PDA) cells reprogram their transcriptional and metabolic programs to survive the nutrient-poor tumor microenvironment. Through in vivo CRISPR screening, we discovered islet-2 (ISL2) as a candidate tumor suppressor that modulates aggressive PDA growth. Notably, ISL2, a nuclear and chromatin-associated transcription factor, is epigenetically silenced in PDA tumors and high promoter DNA methylation or its reduced expression correlates with poor patient survival. The exogenous ISL2 expression or CRISPR-mediated upregulation of the endogenous loci reduces cell proliferation. Mechanistically, ISL2 regulates the expression of metabolic genes, and its depletion increases oxidative phosphorylation (OXPHOS). As such, ISL2-depleted human PDA cells are sensitive to the inhibitors of mitochondrial complex I in vitro and in vivo. Spatial transcriptomic analysis shows heterogeneous intratumoral ISL2 expression, which correlates with the expression of critical metabolic genes. These findings nominate ISL2 as a putative tumor suppressor whose inactivation leads to increased mitochondrial metabolism that may be exploitable therapeutically.
Collapse
Affiliation(s)
- Harun Ozturk
- Northwestern University Feinberg School of Medicine, Robert Lurie Comprehensive Cancer Center, Department of Obstetrics and Gynecology, Chicago, IL 60611, USA
| | - Harun Cingoz
- Northwestern University Feinberg School of Medicine, Robert Lurie Comprehensive Cancer Center, Department of Obstetrics and Gynecology, Chicago, IL 60611, USA
| | - Turan Tufan
- Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine, Charlottesville, VA 22903, USA
| | - Jiekun Yang
- Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine, Charlottesville, VA 22903, USA
| | - Sara J Adair
- Department of Surgery, University of Virginia School of Medicine, Charlottesville, VA 22903, USA
| | | | - Cem Kuscu
- Department of Biochemistry and Molecular Genetics, University of Virginia School of Medicine, Charlottesville, VA 22903, USA
| | - Meric Kinali
- Northwestern University Feinberg School of Medicine, Robert Lurie Comprehensive Cancer Center, Department of Obstetrics and Gynecology, Chicago, IL 60611, USA
| | | | - Sarbajeet Nagdas
- Department of Cell, Immunology and Cancer Biology, University of Virginia School of Medicine, Charlottesville, VA 22903, USA
| | - Bernadette J Goudreau
- Department of Surgery, University of Virginia School of Medicine, Charlottesville, VA 22903, USA
| | | | - Yagmur Bingul
- Northwestern University Feinberg School of Medicine, Robert Lurie Comprehensive Cancer Center, Department of Obstetrics and Gynecology, Chicago, IL 60611, USA
| | - Timothy B Ware
- Department of Chemistry, University of Virginia, Charlottesville, VA 22904, USA
| | - Wiliam L Hwang
- Harvard Medical School, Massachusetts General Hospital, Boston, MA 02114, USA
| | - Ku-Lung Hsu
- Department of Chemistry, University of Virginia, Charlottesville, VA 22904, USA
| | - David F Kashatus
- Department of Cell, Immunology and Cancer Biology, University of Virginia School of Medicine, Charlottesville, VA 22903, USA
| | - David T Ting
- Harvard Medical School, Massachusetts General Hospital, Boston, MA 02114, USA
| | - Navdeep S Chandel
- Northwestern University Feinberg School of Medicine, Robert Lurie Comprehensive Cancer Center, Department of Pulmonary and Critical Care and Department of Biochemistry and Molecular Genetics, Chicago, IL 60611, USA
| | - Nabeel Bardeesy
- Harvard Medical School, Massachusetts General Hospital, Boston, MA 02114, USA
| | - Todd W Bauer
- Department of Surgery, University of Virginia School of Medicine, Charlottesville, VA 22903, USA
| | - Mazhar Adli
- Northwestern University Feinberg School of Medicine, Robert Lurie Comprehensive Cancer Center, Department of Obstetrics and Gynecology, Chicago, IL 60611, USA.
| |
Collapse
|
2
|
Alptekin D, Izmirli M, Bayazit Y, Luleyap HU, Yilmaz MB, Soyupak B, Erkoc MA, Tansug Z. Evaluation of the effects of androgen receptor gene trinucleotide repeats and prostate-specific antigen gene polymorphisms on prostate cancer. Genet Mol Res 2012; 11:1424-32. [PMID: 22653589 DOI: 10.4238/2012.may.18.1] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
The number of trinucleotide repeats [CAG (coding for polyglutamine), GGC (coding for polyglycine)] in the first exon of the androgen receptor (AR) gene and prostate-specific antigen (PSA) gene androgen response element I A/G polymorphism are both related to prostate cancer prognosis. We investigated whether these genomic changes occur in the AR and PSA genes, which are usually found in individuals with prostate cancer, of Turkish patients and to find out their distribution in the population. We used PCR and PCR-RFLP assays for AR and PSA genes, respectively, to detect molecular changes in 44 prostate cancer patients. Our findings indicate that individuals with prostate cancer tend to have around 18 CAG trinucleotide repeats. We observed significant differences between 22 controls, 33 benign prostate hyperplasia (BPH) patients and 44 adenocarcinoma patients for long CAG repeats. However, we did not find any significant differences in GGC repeats between controls, BPH and adenocarcinoma patients (P = 0.408). We also did not observe significant differences in the PSA A/G polymorphism frequency between controls, BPH and adenocarcinoma patients (P = 0.483). In conclusion, CAG and GGC repeats in the AR and PSA gene polymorphisms may be associated with prostate cancer risk and BPH in the Turkish population.
Collapse
Affiliation(s)
- D Alptekin
- Department of Medical Biology, Faculty of Medicine, University of Cukurova, Adana, Turkey.
| | | | | | | | | | | | | | | |
Collapse
|